PT  - JOURNAL ARTICLE
AU  - Pourfarzi, Farhad
AU  - Pakrouy, Hossein
AU  - Mohammadian Erdi, Ali
AU  - Faghfuri, Elnaz
TI  - The Effect of <sup>131</sup>I Therapy on the Eradication of <em>Helicobacter pylori</em> in Patients with Thyroid Disorders: A Preliminary Study
AID  - 10.2967/jnmt.123.266508
DP  - 2024 Jun 01
TA  - Journal of Nuclear Medicine Technology
PG  - 144--147
VI  - 52
IP  - 2
4099  - http://tech.snmjournals.org/content/52/2/144.short
4100  - http://tech.snmjournals.org/content/52/2/144.full
SO  - J. Nucl. Med. Technol.2024 Jun 01; 52
AB  - The leading cause of gastritis and its complications is Helicobacter pylori. Radioactive iodine (131I) accumulates significantly in the stomach after consumption. On this basis, we decided to determine whether different doses of 131I in the stomach would be effective in eradicating the infection. Methods: All patients with hyperthyroidism or differentiated thyroid carcinoma who were referred for 131I treatment were invited to the study. A stool antigen test was conducted before consumption of 131I (0.15–5.5 GBq) and was repeated 2 mo later to detect H. pylori infection. Results: H. pylori positivity was found in 51.8% (14/27) of the patients. At 2 mo after treatment, 13 of the 14 patients with differentiated thyroid carcinoma or hyperthyroidism who had been identified as positive for H. pylori stool antigen before 131I administration were still positive, representing a nonsignificant eradication rate of 7.1%. Conclusion: Administration of 131I to patients with H. pylori did not show potential to eliminate the infection.